butyric acid has been researched along with Non-alcoholic Fatty Liver Disease in 18 studies
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.
butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study demonstrates that ECD regulates the gut microbiota and promotes butyric acid production to ameliorate obesity-related hepatic steatosis." | 8.31 | Erchen Decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid β-oxidation. ( Bi, T; Chen, N; Zhan, L; Zhang, L; Zhou, W; Zhu, L, 2023) |
| "This study demonstrates that ECD regulates the gut microbiota and promotes butyric acid production to ameliorate obesity-related hepatic steatosis." | 4.31 | Erchen Decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid β-oxidation. ( Bi, T; Chen, N; Zhan, L; Zhang, L; Zhou, W; Zhu, L, 2023) |
| " Liver damage, markers of glucose metabolism, inflammation, intestinal barrier function and melatonin metabolism were determined." | 3.96 | Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis. ( Baumann, A; Bergheim, I; Brandt, A; Burkard, M; Jin, CJ; Nier, A; Sellmann, C; Venturelli, S, 2020) |
| "NaB may prevent high-sucrose-induced NAFLD by repressing the fatty acid synthesis pathway." | 1.72 | Dietary Supplementation with Sodium Butyrate Reduces High-sucrose Diet-induced Hepatic Accumulation of Triacylglycerols and Expression of Fatty Acid Synthesis Enzymes in Rats. ( Hattori, Y; Kobayashi, Y; Nakagawa, T; Shimada, M; Tsutsui, S; Yamada, C, 2022) |
| "Sodium butyrate attenuated NAFLD progression by regulating miR-150." | 1.62 | Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression. ( Qin, B; Qu, Y; Zhang, N, 2021) |
| "Butyric acid is an intestinal microbiota-produced short-chain fatty acid, which exerts salutary effects on alleviating nonalcoholic fatty liver disease (NAFLD)." | 1.62 | Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. ( Bai, J; Cai, G; Cui, A; Dai, X; Fan, JG; Han, Y; Hu, Z; Li, Y; Liu, XL; Liu, Y; Liu, Z; Ma, F; Pan, Q; Ren, TY; Shen, F; Su, W; Wang, ZX; Xin, FZ; Xue, Y; Zhang, F; Zhao, ZH; Zhou, D, 2021) |
| "SIRT3 deficiency promotes NAFLD progression in correlation with impaired intestinal permeability through gut microbiota dysbiosis." | 1.51 | SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis. ( Chen, M; Hui, S; Kang, C; Lang, H; Mi, M; Yi, L; Zeng, X; Zhang, Q; Zhang, Y; Zhou, M, 2019) |
| "Similarly, in the NAFLD mouse model, mice fed with a high-fat diet showed reduced hepatic GLP-1R expression, which was reversed by NaB treatment and accompanied by markedly alleviated liver steatosis." | 1.48 | Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. ( Chen, YW; Fan, JG; Liu, XL; Pan, Q; Xin, FZ; Yang, RX; Zhao, ZH; Zhou, D; Zhou, H, 2018) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease." | 1.39 | Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. ( Calignano, A; Canani, RB; Ferrante, MC; Iacono, A; Mattace Raso, G; Meli, R; Paciello, O; Russo, R; Santoro, A; Simeoli, R, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 11 (61.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, N | 2 |
| Qin, B | 2 |
| Hattori, Y | 1 |
| Tsutsui, S | 1 |
| Yamada, C | 1 |
| Kobayashi, Y | 1 |
| Nakagawa, T | 1 |
| Shimada, M | 1 |
| Yu, HR | 1 |
| Sheen, JM | 1 |
| Hou, CY | 1 |
| Lin, IC | 1 |
| Huang, LT | 1 |
| Tain, YL | 1 |
| Cheng, HH | 1 |
| Lai, YJ | 1 |
| Lin, YJ | 1 |
| Tiao, MM | 1 |
| Tsai, CC | 1 |
| Shashni, B | 1 |
| Tajika, Y | 1 |
| Ikeda, Y | 1 |
| Nishikawa, Y | 1 |
| Nagasaki, Y | 1 |
| Sarkar, A | 1 |
| Mitra, P | 1 |
| Lahiri, A | 1 |
| Das, T | 1 |
| Sarkar, J | 1 |
| Paul, S | 1 |
| Chakrabarti, P | 1 |
| Zhang, L | 2 |
| Chen, N | 1 |
| Zhan, L | 1 |
| Bi, T | 1 |
| Zhou, W | 1 |
| Zhu, L | 1 |
| Baumann, A | 1 |
| Jin, CJ | 2 |
| Brandt, A | 1 |
| Sellmann, C | 2 |
| Nier, A | 1 |
| Burkard, M | 1 |
| Venturelli, S | 1 |
| Bergheim, I | 2 |
| Deng, M | 1 |
| Qu, F | 1 |
| Chen, L | 1 |
| Liu, C | 2 |
| Zhang, M | 1 |
| Ren, F | 1 |
| Guo, H | 1 |
| Zhang, H | 1 |
| Ge, S | 1 |
| Wu, C | 1 |
| Zhao, L | 1 |
| Yang, T | 1 |
| Yang, H | 1 |
| Heng, C | 1 |
| Wang, H | 1 |
| Chen, S | 1 |
| Hu, Y | 2 |
| Jiang, Z | 1 |
| Yu, Q | 1 |
| Wang, Z | 1 |
| Qian, S | 1 |
| Wang, J | 1 |
| Wang, T | 1 |
| Du, L | 1 |
| Lu, Q | 1 |
| Yin, X | 1 |
| Qu, Y | 1 |
| Zhao, ZH | 2 |
| Wang, ZX | 1 |
| Zhou, D | 4 |
| Han, Y | 1 |
| Ma, F | 1 |
| Hu, Z | 1 |
| Xin, FZ | 3 |
| Liu, XL | 2 |
| Ren, TY | 1 |
| Zhang, F | 1 |
| Xue, Y | 1 |
| Cui, A | 1 |
| Liu, Z | 1 |
| Bai, J | 1 |
| Liu, Y | 1 |
| Cai, G | 1 |
| Su, W | 1 |
| Dai, X | 1 |
| Shen, F | 2 |
| Pan, Q | 4 |
| Li, Y | 1 |
| Fan, JG | 4 |
| Cao, HX | 1 |
| Ding, WJ | 1 |
| Chen, YW | 3 |
| Sun, B | 1 |
| Jia, Y | 1 |
| Hong, J | 1 |
| Sun, Q | 1 |
| Gao, S | 1 |
| Zhao, N | 1 |
| Zhao, R | 1 |
| Yang, RX | 1 |
| Zhou, H | 1 |
| Chen, M | 1 |
| Hui, S | 1 |
| Lang, H | 1 |
| Zhou, M | 1 |
| Zhang, Y | 1 |
| Kang, C | 1 |
| Zeng, X | 1 |
| Zhang, Q | 1 |
| Yi, L | 1 |
| Mi, M | 1 |
| Mattace Raso, G | 1 |
| Simeoli, R | 1 |
| Russo, R | 1 |
| Iacono, A | 1 |
| Santoro, A | 1 |
| Paciello, O | 1 |
| Ferrante, MC | 1 |
| Canani, RB | 1 |
| Calignano, A | 1 |
| Meli, R | 1 |
| Engstler, AJ | 1 |
| Ziegenhardt, D | 1 |
| Zhang, RN | 1 |
| He, CX | 1 |
| Chen, GY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495] | 57 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for butyric acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
[Research progress of sodium butyrate in metabolic-associated fatty liver disease].
Topics: Butyric Acid; Fatty Liver; Humans; Lipid Metabolism; Liver Diseases; Non-alcoholic Fatty Liver Disea | 2021 |
17 other studies available for butyric acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Dietary Supplementation with Sodium Butyrate Reduces High-sucrose Diet-induced Hepatic Accumulation of Triacylglycerols and Expression of Fatty Acid Synthesis Enzymes in Rats.
Topics: Animals; Butyric Acid; Diet; Dietary Supplements; Liver; Non-alcoholic Fatty Liver Disease; Rats; Su | 2022 |
Effects of Maternal Gut Microbiota-Targeted Therapy on the Programming of Nonalcoholic Fatty Liver Disease in Dams and Fetuses, Related to a Prenatal High-Fat Diet.
Topics: Animals; Butyric Acid; Diet, High-Fat; Fatty Acids, Volatile; Female; Fetus; Gastrointestinal Microb | 2022 |
Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis.
Topics: Animals; Butyric Acid; Disease Models, Animal; Fatty Acids, Volatile; Liver; Liver Cirrhosis; Mice; | 2023 |
Butyrate limits inflammatory macrophage niche in NASH.
Topics: Animals; Butyric Acid; Lipopolysaccharides; Liver; Macrophages; Mice; Mice, Inbred C57BL; Non-alcoho | 2023 |
Erchen Decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid β-oxidation.
Topics: Animals; Butyric Acid; Diet, High-Fat; Fatty Acids, Volatile; Gastrointestinal Microbiome; Mice; Mic | 2023 |
Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis.
Topics: Animals; Butyric Acid; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Disease Models, An | 2020 |
SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD.
Topics: Acetates; Alanine Transaminase; Animals; Aspartate Aminotransferases; Butyrates; Butyric Acid; Fatty | 2020 |
Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice.
Topics: Animals; Blood Glucose; Butyric Acid; Caco-2 Cells; Cholesterol; Clostridium butyricum; Colon; Cytok | 2020 |
Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
Topics: Alanine Transaminase; Animals; Butyric Acid; Diet, High-Fat; Disease Models, Animal; Non-alcoholic F | 2021 |
Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene.
Topics: AMP-Activated Protein Kinases; Animals; Butyric Acid; Diet, High-Fat; Dietary Supplements; Disease M | 2021 |
Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.
Topics: Adipose Tissue; Animals; Body Weight; Butyric Acid; Cecum; Diet, High-Fat; Endotoxemia; Epididymis; | 2017 |
Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
Topics: Animals; Butyric Acid; Cytokines; Diet, High-Fat; Fatty Acids; Histone Deacetylase 1; Histones; Huma | 2018 |
Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
Topics: Adult; Animals; Butyric Acid; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regu | 2018 |
SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
Topics: Animals; Butyric Acid; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Intestinal Absorption | 2019 |
Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet.
Topics: Adipose Tissue; Amides; Animals; Butyric Acid; Diet, High-Fat; Disease Models, Animal; Enzyme Activa | 2013 |
Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Butyric Acid; Diet, Western; Dietary S | 2015 |
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
Topics: Animals; Butyric Acid; Cytokines; Diet, High-Fat; Drug Evaluation, Preclinical; Dysbiosis; Gastroint | 2017 |